Related Experiment Video
Updated: Aug 9, 2025
Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
In silico target specific design of potential quinazoline-based anti-NSCLC agents
Elaheh Mohammadnejadi1, Nima Razzaghi-Asl2
1Students Research Committee, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
Abstract:
Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. In spite of great advances, treatment of the disease is a medical challenge. Epidermal-growth factor receptor (EGFR) has been taken as a promising cell surface target to develop anti-NSCLC therapies. The main bottleneck to attain clinical efficacy with current EGFR tyrosine kinase inhibitors (EGFR-TKIs) is the rapid spread of oncogenic mutations. Numerous efforts have been made for the synthesis of diverse EGFR-TKIs against resistance-conferring mutations. One of the best strategies to design potent agents would be to explore existing anti-NSCLC drugs at the nonclinical development stage and prioritize privileged structural patterns. Within current study, conformational stability of clinically frequent EGFR mutants (G719S, T790M, L858R and a double mutant form L858R/T790M) were validated via DynaMut and missense3D computational servers. Subsequently, structure activity relationship (SAR) and scaffold similarity inquiry were used to rationally propose a few erlotinib analogues. Intended molecules were subjected to molecular docking and top-scored binders were further analyzed through 50-ns all atom molecular dynamics (MD) simulations to infer the dynamic behavior. The aim was to offer potential binders to overwhelm clinically frequent EGFR-TK mutants. The linear interaction energy (LIE) method was applied to compute the binding free energies between EGFR and intended ligands. For this purpose, MD-based conformational sampling of ligand-enzyme complexes and ligand-water associations were used to acquire thermodynamic energy averages. Though mechanistic details are to be explored, results of the current study identify synthetically accessible quinazoline small molecules with potential affinity toward frequent EGFR-TK mutants.[Figure: see text]Communicated by Ramaswamy H. Sarma.
Insights
This study computationally identifies novel quinazoline compounds with potential to overcome resistance in non-small cell lung cancer (NSCLC) by targeting common epidermal growth factor receptor (EGFR) mutations. These findings offer new therapeutic strategies for difficult-to-treat NSCLC.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Oncology
Background:
- Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, posing a significant therapeutic challenge.
- Epidermal growth factor receptor (EGFR) is a key target for NSCLC therapy, but resistance through mutations limits current drug efficacy.
- Developing novel inhibitors that overcome resistance-conferring EGFR mutations is crucial for improving patient outcomes.
Purpose of the Study:
- To computationally identify and analyze novel small molecules targeting clinically relevant epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutants.
- To explore structure-activity relationships and scaffold similarities of existing drugs to design new potential inhibitors.
- To evaluate the binding affinity and dynamic behavior of proposed analogues against common EGFR mutations.
Main Methods:
- Validated conformational stability of EGFR mutants (G719S, T790M, L858R, L858R/T790M) using DynaMut and missense3D.
- Employed structure-activity relationship (SAR) and scaffold similarity analysis to propose erlotinib analogues.
- Utilized molecular docking, 50-ns all-atom molecular dynamics (MD) simulations, and linear interaction energy (LIE) method for binding free energy calculations.
Main Results:
- Identified synthetically accessible quinazoline small molecules demonstrating potential affinity for common EGFR-TK mutants.
- Molecular dynamics simulations provided insights into the dynamic behavior and interactions of the proposed ligands with EGFR mutants.
- Binding free energies were computed using the LIE method, indicating potential efficacy against resistant mutations.
Conclusions:
- The study successfully identified novel quinazoline-based compounds with potential to inhibit clinically frequent EGFR-TK mutants.
- These compounds represent promising candidates for further nonclinical development as anti-NSCLC agents, particularly against resistant forms.
- The findings contribute to the rational design of next-generation EGFR inhibitors for NSCLC treatment.
More Related Videos
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:26Drug Discovery: Overview